What is the preferred antifungal medication, fluconazole (FLU) or itraconazole (ITR), for a patient with impaired renal function and a history of candidiasis or aspergillosis?

Fluconazole vs Itraconazole: Antifungal Coverage and Selection

Direct Recommendation

Fluconazole is the preferred azole antifungal for most candidal infections, particularly in patients with renal impairment, due to superior pharmacokinetics, better tolerability, fewer drug interactions, and no dose adjustment required in renal dysfunction. 1, 2 Itraconazole has minimal role in candidemia and candidiasis management compared to fluconazole. 1

---

Coverage Spectrum Comparison

Fluconazole Coverage

• Excellent activity against:

  • Candida albicans 1
  • Candida parapsilosis (preferred over echinocandins) 1, 3
  • Candida tropicalis 1, 3
  • Cryptococcus neoformans 4

• Poor/No activity against:

  • Candida krusei (intrinsically resistant) 1, 3
  • Candida glabrata (variable susceptibility, often requires higher doses) 1, 3
  • Aspergillus species 4
  • Filamentous fungi 5

Itraconazole Coverage

• Activity against:

  • Aspergillus species 5
  • Endemic fungi 5
  • Some Candida species 1

• Limited utility for:

  • Candidemia (fluconazole superior) 1
  • Systemic candidiasis 1

---

Clinical Selection Algorithm

For Candidal Infections

Step 1: Identify infection site and severity

• Candidemia/Invasive Candidiasis:

  • Fluconazole 800 mg loading dose, then 400 mg daily for mild-moderate illness in hemodynamically stable patients without recent azole exposure 1
  • Itraconazole has no role in this setting 1

• Oropharyngeal Candidiasis:

  • Fluconazole: First-line (AI recommendation) 1
  • Itraconazole solution: Alternative (BIIt recommendation) 1

• Esophageal Candidiasis:

  • Fluconazole: First-line (AIIt recommendation) 1
  • Itraconazole: Alternative (BIIt recommendation) 1

• Urinary Tract Candidiasis:

  • Fluconazole: Only azole option due to high urinary concentrations of active drug 1
  • Itraconazole: Not useful (minimal active drug excretion in urine) 1

• Vulvovaginal Candidiasis:

  • Fluconazole 150 mg single dose (A-I recommendation) 1, 6
  • Itraconazole: Not recommended 1

Step 2: Consider renal function

• Impaired renal function:
  • Fluconazole: Dose adjustment required only for multiple doses; loading dose given normally, then reduce maintenance dose by 50% if CrCl ≤50 mL/min 2
  • Itraconazole: Limited data; use with caution 7

Step 3: Assess species and resistance risk

• High risk for C. glabrata or C. krusei:

  • Neither fluconazole nor itraconazole recommended as first-line 1
  • Consider echinocandin initially 1

• C. parapsilosis confirmed:

  • Fluconazole preferred over echinocandins 1

For Aspergillosis

• Itraconazole has historical role in aspergillosis treatment 5
• Fluconazole has no activity against Aspergillus 4
• Voriconazole or newer agents preferred for invasive aspergillosis 1

---

Key Pharmacokinetic Advantages: Fluconazole

Why Fluconazole is Superior for Most Candidal Infections

1. Renal excretion: High urinary concentrations of active drug make it ideal for urinary candidiasis 1, 2

2. Predictable absorption: High water solubility, consistent bioavailability 4, 6

3. Minimal drug interactions: Fewer than itraconazole 1, 5

4. Better tolerability: Lower toxicity profile 1, 4

5. Convenient dosing: Once daily, can be given with or without food 2

Why Itraconazole is Problematic

1. Erratic bioavailability: Especially with capsule formulation (solution better but still variable) 5

2. Numerous drug interactions: More extensive than fluconazole 5

3. Poor urinary excretion: Minimal active drug in urine 1

4. Food requirements: Absorption issues limit utility 5

---

Critical Renal Function Considerations

Fluconazole Dosing in Renal Impairment

• CrCl >50 mL/min: No adjustment needed 2
• CrCl ≤50 mL/min (no dialysis): Give 50% of normal dose after loading dose 2
• Hemodialysis: Give 100% dose after each dialysis session 2

Itraconazole in Renal Impairment

• Limited data available 7
• Use with caution in this population 7
• Not preferred choice when renal function is impaired 7

---

Common Pitfalls to Avoid

1. Do not use fluconazole for C. krusei infections: This species is intrinsically resistant 1, 3

2. Do not use itraconazole for candidemia: Fluconazole has superior pharmacokinetics, ease of administration, and tolerability for this indication 1

3. Do not use either agent for suspected aspergillosis in immunocompromised patients: Fluconazole lacks activity; itraconazole has been superseded by voriconazole 1, 5

4. Do not use itraconazole for urinary candidiasis: Inadequate urinary concentrations make it ineffective 1

5. Do not assume C. glabrata susceptibility to fluconazole: This species often requires higher doses or alternative agents 1, 3

6. Do not use fluconazole <400 mg daily for serious infections in adults with normal renal function: Inadequate dosing leads to treatment failure 1

---

Special Populations

Immunocompromised/Neutropenic Patients

• Candidemia: Fluconazole appropriate only if no recent azole exposure and hemodynamically stable 1
• Empiric therapy in neutropenia: Itraconazole 200 mg twice daily is an option (B-I recommendation) but other agents often preferred 1

Transplant Recipients

• Prophylaxis: Both fluconazole and itraconazole have roles, but fluconazole preferred for anti-Candida prophylaxis due to better tolerability 1
• Treatment: Follow same principles as non-transplant patients 1